NCT03282357已完成不适用
Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 181
- 试验地点
- 6
- 主要终点
- Percentage of NLFs With Treatment Success at Month 6
研究概览
简要总结
The objectives of this study are to evaluate the effectiveness and safety of Radiesse for the correction of nasolabial folds (NLFs).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is 22 - 65 years of age.
- •Has symmetrical NLFs of moderate or severe intensity (grade 3 or 4) on the WSRS as determined by the independent blinded evaluator and confirmed by the treating investigator at baseline.
- •Both folds must have the same NLF score at baseline.
- •Has signed an informed consent.
- •Understands and accepts the obligation not to receive any other facial procedures below the eyes during the study.
- •Understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
- •Subjects of childbearing potential must have a negative pregnancy test result and must not be lactating at the Screening/Baseline Visit and be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will be considered if one of the following conditions is documented on the medical history:
- •Postmenopausal with last menstrual bleeding at least 12 months prior to study; and
- •Without a uterus and/or both ovaries.
排除标准
- •Has received surgical permanent implants, grafting, or surgery below the eyes on the face prior to injection or lower lid blepharoplasty within 6 months prior to injection.
- •Has received within the specified (washout) period or plans to receive treatment during the study conduct with a non-permanent facial filler in any facial area below the eyes:
- •12 months prior to study start - hyaluronic acid [HA] or collagen
- •18 months prior to study start - calcium hydroxylapatite [CaHA]
- •Has received at any time or plans to receive during the study a permanent facial filler (e.g. poly L-lactic acid [PLLA], polymethyl-methacrylate [PMMA], silicone) below the eyes.
- •Has received within the past 6 months or plans to receive during the study facial dermal resurfacing procedures (e.g. chemical peel, dermabrasion, ablative laser resurfacing), non-invasive skin-tightening (e.g. Thermage), botulinum toxin injections, mesotherapy, or fat injections below the eyes.
- •Has received in the past 2 weeks or plans to receive during the study any prescription wrinkle therapies (e.g. RENOVAÒ), topical steroids, skin irritating topical preparations, or pigmenting agents (self-tanning agents) for use on the face.
- •Has received in the past 2 months, or plans to receive immunosuppressive medications or systemic steroids (intranasal/inhaled steroids acceptable) during the study.
- •Has an acute inflammatory process or infection, active herpes infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events (AEs).
- •Has a known bleeding disorder or has received or is planning to receive anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs (e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, garlic, gingko), from 10 days before injection to 3 days after injection.
- •Has a history of known liver or renal function disease/disorder or has clinically significant laboratory values at baseline.
- •Has a known history of allergic/anaphylactic reactions, including hypersensitivity to lidocaine or anesthetics of the amide type, or any of the device components.
- •Has a history of hyper- or hypo-pigmentation in the NLFs, keloid formation, or hypertrophic scarring.
- •Has recently lost or has the intention to lose a significant amount of weight ≥ 2 Body Mass Index (BMI) units during the course of the study.
- •Has any other medical condition with the potential to interfere with the study's conduct or assessments, or increase the risk of AEs.
- •Has participated in a study in the last 30 days or is enrolled or plans to enroll in any other interfering investigational study during participation in the study.
- •Is an employee or direct relative of an employee of the investigational department in site or the sponsor.
结局指标
主要结局
Percentage of NLFs With Treatment Success at Month 6
时间窗: Month 6
Treatment success was defined as a greater than or equal to (\>=) 1-point improvement from baseline, as assessed by a blinded evaluator wrinkle severity rating scale (WSRS) scale. WSRS is a 5 point scale with scores as Score 1: Absent; Score 2: Mild; Score 3: Moderate; Score 4: Severe; Score 5: Extreme.
次要结局
- Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6(Month 6)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial FoldsCorrection of Moderate to Severe Nasolabial Folds (NLFs)NCT04647721Merz North America, Inc.134
已完成
不适用
Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the JawlineImprovement of Jawline ContourNCT03583359Merz North America, Inc.180
Unknown
2 期
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersThyroidMetastasisApatinibNCT04180007Nanjing First Hospital, Nanjing Medical University10
已完成
不适用
Radiesse® Safety Study For the Treatment of HandsVolume Loss in the Dorsum of the HandNCT02904096Merz North America, Inc.256
招募中
1 期
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomaNCT04443010Philogen S.p.A.226